Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate

American Journal of Dermatopathology

Volumn 32, Issue 1, 2010, Pages 65-70

  Huwait, Hassan ^a   Wang, Beatrice ^a   Shustik, Chaim ^a   Michel, René P ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

B cell lymphoma; Composite lymphoma; Cutaneous lymphoma; Methotrexate; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUNCH BIOPSY; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN LYMPHOMA; T LYMPHOCYTE;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DNA, NEOPLASM; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; GENE REARRANGEMENT, T-LYMPHOCYTE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; METHOTREXATE; NEOPLASMS, MULTIPLE PRIMARY; SKIN NEOPLASMS;

EID: 77649096626     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181af7dee     Document Type: Article

References (19)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-1751. (Pubitemid 38725085)
3. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322-331.
4. Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. Am J Med. 1985;78:22-28.
5. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31:691-696.
6. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85:307-311.
7. Starkebaum G. Rheumatoid arthritis and lymphoma: risky business for B cells. J Rheumatol. 2007;34:243-246.
8. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14: 1943-1949.
9. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60.
10. Kazakov DV, Kutzner H, Palmedo G, et al. Primary cutaneous lymphoproliferative disorders with dual lineage rearrangement. Am J Dermatopathol. 2006;28:399-409.
11. Gallardo F, Pujol RM, Bellosillo B, et al. Primary cutaneous B-cell lymphoma (marginal zone) with prominent T-cell component and aberrant dual (T and B) genotype; diagnostic usefulness of laser-capture microdissection. Br J Dermatol. 2006;154:162-166.
12. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
13. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909-3915.
14. Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26:794-804.
15. Bachman TR, Sawitzke AD, Perkins SL, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum. 1996;39:325-329.
16. Kamel OW, van de Rijn M, LeBrun DP, et al. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol. 1994;25:638-643.
17. Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med. 1981;305: 1238-1243.
18. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15: 2069-2077.
19. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82.